Shots:The US FDA has approved the PMA application for Idylla CDx MSI Test, a cartridge-based, fully automated “sample-to-result” companion diagnostic, with US launch anticipated soon & availability in other non-US markets to followThe Idylla CDx MSI Test helps identify MSI-H colorectal cancer pts eligible for Opdivo (nivolumab) alone or with Yervoy (ipilimumab), as…
Shots:Agilent Technologies has received the US FDA approval for its MMR IHC Panel pharmDx (Dako Omnis) as a companion diagnostic (CDx) test for colorectal cancerAgilent & BMS partnered to develop the MMR IHC Panel pharmDx (Dako Omnis) to identify dMMR colorectal cancer pts eligible for Opdivo monotx. or Opdivo + Yervoy treatmentThe…
Shots:Garret spoke about the approval of the first NGS-based companion diagnostic to aid in selecting NSCLC patients with HER2 activating mutations for treatment with ENHERTUGarret also talked about the Oncomine Dx Target Test and its availability for different targeted therapies in multiple geographiesThe interview highlights how Thermo Fisher is working to develop accessible CDx solutions…

